OncoMatch/Clinical Trials/NCT05536102
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Is NCT05536102 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including PLD and Oxaliplatin for gastric cancer.
Treatment: PLD · Oxaliplatin · Capecitabine · Tislelizumab — This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the neoadjuvant treatment of resectable gastric adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) negative
HER2-
Required: PD-L1 (CD274) positive
PD-1/L1+
Disease stage
Required: Stage III
Demographics
Prior therapy
Cannot have received: chemotherapy
Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer
Cannot have received: radiation therapy
Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer
Cannot have received: immunotherapy
Received chemotherapy, radiotherapy or immunotherapy for this gastric cancer
Lab requirements
Blood counts
hemoglobin ≥90g/L; ANC ≥1.5×10^9/L; platelets ≥100×10^9/L; serum albumin ≥30g/L
Kidney function
serum creatinine <1 ULN; creatinine clearance >50 ml/min
Liver function
ALT, AST ≤2.5x ULN; serum total bilirubin <1.5 ULN
Cardiac function
LVEF ≥50%; 12-ECG indicates no myocardial ischemia; no history of arrhythmia requiring drug intervention before enrollment
Subject baseline blood routine and biochemical indicators meet the following standards: hemoglobin ≥90g/L; absolute neutrophil count (ANC) ≥1.5×10^9g/L; platelets counts (PLT) ≥100×10^9/L; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal (ULN); serum total bilirubin <1.5 ULN; serum creatinine <1 ULN; serum albumin ≥30g/L. Heart function: Left ventricular ejection fraction (LVEF) ≥50%; 12-ECG indicates no myocardial ischemia; No history of arrhythmia requiring drug intervention before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05536102 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages